Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2074678
Reference Type
Technical Report
Title
Antagonists For Toxic Heavy Metals
Author(s)
Jones, MM
Year
1984
Report Number
NIOSH/00146611
Volume
27
Page Numbers
163-167
Abstract
Antagonists for toxic heavy metals are reviewed. Antagonism of the toxic action of heavy metals is generally based on manipulating bonding preferences of the toxic metal through transfer to an appropriate metal/chelate complex. Donor preferences of the metal ions must be studied to estimate effectiveness of proposed chelating agents and their rate of replacement. The acceptor preferences of the chelating agents represent the other side of the coin. Chelating agents of therapeutic usefulness are not specific for a given metal ion but can be matched to a number of ions with related patterns of behavior. If measured values of the stability constants are available they can give a clue as to the best chelate antagonists for a given toxic metal. The chelating agent must reach the toxic ion, form a complex with it, and be disposed of, preferably by excretion. The mode of excretion can have an effect on the net detoxification achieved. For many toxic metals delay in the beginning of chelation therapy results in increased permanent damage. Non chelate antagonists also cover a variety of situations. Absorption in the gastrointestinal tract, for example, is useful if orally ingested thallium is not yet absorbed by the intestines. Ascorbic-acid is an antidote for vanadate. The use of non chelate antagonists sometimes allows a completely different therapeutic approach but there seems to be no reliable technique for predicting efficiency of non chelates prior to experimentation. There are many unsolved problems in antagonizing toxic heavy metals. Thallium and some of the rare earths require development of more effective agents. An oral agent is needed to induce excretion of iron from persons receiving multiple blood transfusions. Aluminum, cis-platinum, gallium-nitrate, selenium, and the organometallic compounds all require further study. The author concludes that, in general, methods are needed to shift excretion of toxic metals from the sensitive renal route to the less sensitive fecal route.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity